eMS News

The annual open enrollment period for insurance plans is underway from November 1st until December 15th. It is very important to review your health insurance plan before you renew. There are changes…

An initial lab study has shown metformin, a common diabetes drug, can repair nerve damage caused by MS; Researchers plan to conduct human trial next year.  Recently, results from animal…

Dr. John Corboy, Co-Director of the Rocky Mountain MS Center at University of Colorado, has been named the inaugural Charles Elliot Morris Chair in Neurology. Dr. Corboy serves as Co-Director…

The US Food and Drug Administration (FDA) has approved oral cladribine (brand named Mavenclad®, EMD Serono) for the treatment of adults with relapsing forms of MS, including relapsing-remitting MS and…

The US Food and Drug Administration (FDA) has approved oral Siponimod (brand named Mayzent®, Novartis International AG) to treat clinically isolated syndrome (an initial neurological episode), relapsing forms of MS,…